| Code No. |
MD-10-4 |
|
Anti-Fas (CD95) (Human) mAb-FITC
|
| Size |
100 µL (500 µg/mL) |
| Availability (in Japan) |
10 or more
(In Japan at 00:05, Jun 9, 2026 in JST)
|
| Clonality |
Monoclonal |
| Clone |
UB2 |
Isotype
(Immunized Animal) |
Mouse IgG1 |
| Applications |
FCM 10 µg/mL
|
Immunogen
(Antigen) |
Recombinant Human Fas |
| Reactivity [Gene ID] |
Human[355], Mouse(-) |
| Storage buffer |
500 µg/mL in PBS/1% BSA/0.1% ProClin 150 |
| Storage temp. |
4°C |
| Conjugate |
FITC |
| Manufacturer |
MBL |
| Alternative names |
"APT1, FAS1, APO-1, FASTM, ALPS1A, TNFRSF6" |
| Background |
"It is now widely accepted that apoptosis plays an important role in the selection of immature thymocytes and Ag-primed peripheral T cells. Fas antigen is a cell-surface protein that mediates apoptosis. It is expressed in various tissues including the thymus and has structural homology with a number of cell-surface receptors, including tumor necrosis factor receptor and nerve growth factor receptor." |
| Related products |
SY-001 Anti-Fas (CD95) (Human) mAb MD-10-3 Anti-Fas (CD95) (Human) mAb MD-10-5 Anti-Fas (CD95) (Human) mAb-PE MD-10-A48 Anti-Fas (CD95) (Human) mAb-Alexa Fluor™ 488 MD-11-3 Anti-Fas (CD95) (Human) mAb M075-4 Mouse IgG1 (isotype control)-FITC
|
| Product category |
Research area:Apoptosis Cell surface antigens |
| Data |

|
| Citations |
Flow Cytometry - Yanagisawa J et al. The molecular interaction of Fas and FAP-1. A tripeptide blocker of human Fas interaction with FAP-1 promotes Fas-induced apoptosis. J Biol Chem. 272, 8539-45 (1997)(PMID:9079683)
- Koshiji M et al. Apoptosis of colorectal adenocarcinoma (COLO 201) by tumour necrosis factor-alpha (TNF-alpha) and/or interferon-gamma (IFN-gamma), resulting from down-modulation of Bcl-2. Clin Exp Immunol. 111, 211-8 (1998)(PMID:9472684)
- Sata M et al. Oxidized LDL activates fas-mediated endothelial cell apoptosis. J Clin Invest. 102, 1682-9 (1998)(PMID:9802882)
- Matsumoto Y et al. Peripheral deletion of gammadelta T cells in haemodialysis patients. Nephrol Dial Transplant. 13, 2861-6 (1998)(PMID:9829491)
- Morimoto Y et al. Functional expression of Fas and Fas ligand on human intestinal intraepithelial lymphocytes. Clin Exp Immunol. 116, 84-9 (1999)(PMID:10209509)
- Ohashi M et al. Changes in susceptibility to Fas-mediated apoptosis during differentiation of HL-60 cells. J Leukoc Biol. 67, 374-80 (2000)(PMID:10733098)
- Shinohara H et al. Fas drives cell cycle progression in glioma cells via extracellular signal-regulated kinase activation. Cancer Res. 60, 1766-72 (2000)(PMID:10749152)
- Yuki H et al. A free radical initiator, 2,2'-azobis (2-aminopropane) dihydrochloride enhances hyperthermia-induced apoptosis in human uterine cervical cancer cell lines. Free Radic Res. 37, 631-43 (2003)(PMID:12868490)
- Yamauchi R et al. Different susceptibility of malignant versus nonmalignant human T cells toward ultraviolet A-1 radiation-induced apoptosis. J Invest Dermatol. 122, 477-83 (2004)(PMID:15009733)
- Hamasu T et al. Enhanced induction of apoptosis by combined treatment of human carcinoma cells with X rays and death receptor agonists. J Radiat Res. 46, 103-10 (2005)(PMID:15802865)
- Ennaciri J et al. Induction of apoptosis by herpes simplex virus-1 in neonatal, but not adult, neutrophils. Pediatr Res. 59, 7-12 (2006)(PMID:16327000)
- Tanaka T et al. Differential sensitivity to paclitaxel-induced apoptosis and growth suppression in paclitaxel-resistant cell lines established from HEC-1 human endometrial adenocarcinoma cells. Int J Oncol. 41, 1837-44 (2012)(PMID:22923148)
- Villa-Morales M et al. FAS system deregulation in T-cell lymphoblastic lymphoma.colorectal cancer. Cell Death Dis. 5, e1110 (2014)(PMID:24603338)
|